Perspective article: determinants and assessment of cardiovascular risk in steatotic liver disease owing to metabolic dysfunction-addressing the challenge

Abstract

Metabolic dysfunction-associated steatotic liver disease (MASLD) stands as an independent risk factor for cardiovascular disease (CVD), which is the leading cause of mortality among MASLD patients. The diverse spectrum of cardio-nephro-metabolic and vascular manifestations inherent in MASLD highlights the complex profile of CVD risk associated with this condition. However, current approaches to assessing CVD risk in MASLD lack specificity, predominantly relying on traditional markers. Although it is widely accepted that patients with advanced fibrosis are more prone to CVD risk, recent evidence suggests that this isolated focus may overlook the remarkable phenotypic variability of this CVD risk across the entire MASLD population. Emerging data indicate a progressive escalation of CVD risk in parallel with the severity of MASLD, highlighting the need for precise disease staging to inform accurate risk assessment. To address this challenge, we propose a novel sequential approach to CVD risk assessment in MASLD. While traditional CVD risk factors remain essential, incorporating liver-specific parameters enhances risk stratification and guides targeted interventions to mitigate the substantial burden of cardiovascular disease in this vulnerable population. This approach involves initial screening using FIB-4 and NAFLD fibrosis score, followed by assessment of liver fibrosis with imaging-based non-invasive techniques in individuals at intermediate-high risk for advanced fibrosis and liver fat quantification in low-risk individuals. Future prospective investigations should focus on the simultaneous use of liver biomarkers and imaging modalities to evaluate, in a sex-specific manner, the efficacy of the proposed approach and to determine optimal thresholds of liver fibrosis and steatosis for optimal CVD risk assessment.

Keywords

Biomarkers / cardiovascular risk / elastometry / fibroscan / liver fibrosis / steatosis / ultrasonography

References

[1] Riazi K,Charette JH.The prevalence and incidence of NAFLD worldwide: a systematic review and meta-analysis.Lancet Gastroenterol2022;7:851-61

[2] Mantovani A,Beatrice G,Byrne CD.Non-alcoholic fatty liver disease and risk of incident diabetes mellitus: an updated meta-analysis of 501 022 adult individuals.Gut2021;70:962-9

[3] Lonardo A,Alswat KA.History of nonalcoholic fatty liver disease.Int J Mol Sci2020;21:5888 PMCID:PMC7460697

[4] Konyn P,Kim D.Causes and risk profiles of mortality among individuals with nonalcoholic fatty liver disease.Clin Mol Hepatol2023;29:S43-57 PMCID:PMC10029952

[5] Kim D,Yoo ER.Trends in mortality from extrahepatic complications in patients with chronic liver disease, from 2007 through 2017.Gastroenterology2019;157:1055-66.e11

[6] Duell PB,Miller M.on behalf of the American Heart Association Council on ArteriosclerosisThrombosis and Vascular Biology; Council on Hypertension; Council on the Kidney in Cardiovascular Disease; Council on Lifestyle and Cardiometabolic Health; and Council on Peripheral Vascular DiseaseNonalcoholic fatty liver disease and cardiovascular risk: a scientific statement from the american heart association.Arterioscler Thromb Vasc Biol2022;42:e168-85

[7] Mantovani A,Petracca G.Non-alcoholic fatty liver disease and risk of fatal and non-fatal cardiovascular events: an updated systematic review and meta-analysis.Lancet Gastroenterol Hepatol2021;6:903-13

[8] Jaruvongvanich V,Sanguankeo A,Wijarnpreecha K.Increased arterial stiffness in nonalcoholic fatty liver disease: a systematic review and meta-analysis.Eur J Gastroen Hepat2017;29:e28-35

[9] Wong MYZ,Sultana R,Goh GBB.Association between non-alcoholic fatty liver disease and subclinical atherosclerosis in Western and Asian cohorts: an updated meta-analysis.Open Heart2021;8:e001850 PMCID:PMC8693165

[10] Arnett DK,Albert MA.2019 ACC/AHA guideline on the primary prevention of cardiovascular disease: a report of the American college of cardiology/American heart association task force on clinical practice guidelines.Circulation2019;140:e596-646 PMCID:PMC7734661

[11] Yi M,Teng F,Chen Z.The role of noninvasive scoring systems for predicting cardiovascular disease risk in patients with nonalcoholic fatty liver disease: a systematic review and meta-analysis.Eur J Gastroen Hepat2022;34:1277-84

[12] Jamalinia M,Noorizadeh K.Systematic review with meta-analysis: Steatosis severity and subclinical atherosclerosis in metabolic dysfunction-associated steatotic liver disease.Aliment Pharmacol Ther2024;59:445-58

[13] Jamalinia M,Lankarani KB.Systematic review and meta-analysis: Association between liver fibrosis and subclinical atherosclerosis in nonalcoholic fatty liver disease.Aliment Pharmacol Ther2023;58:384-94

[14] Eslam M,Sarin SK.A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement.J Hepatol2020;73:202-9

[15] Eslam M,George J.MAFLD: a consensus-driven proposed nomenclature for metabolic associated fatty liver disease.Gastroenterology2020;158:1999-2014.e1

[16] Lee H,Kim SU.Metabolic dysfunction-associated fatty liver disease and incident cardiovascular disease risk: a nationwide cohort study.Clin Gastroenterol Hepatol2021;19:2138- 47.e10.

[17] Sung K,Lee MY,Zheng M.Comparative associations of nonalcoholic fatty liver disease and metabolic dysfunction-associated fatty liver disease with coronary artery calcification: a cross-sectional and longitudinal cohort study.ATVB2023;43:482-91

[18] Rinella ME,Ratziu V.A multisociety Delphi consensus statement on new fatty liver disease nomenclature.J Hepatol2023;79:1542-56 PMCID:PMC10653297

[19] Moon JH,Jang H,Kim W.Metabolic dysfunction-associated steatotic liver disease increases the risk of incident cardiovascular disease: a nationwide cohort study.eClinicalMedicine2023;65:102292 PMCID:PMC10632413

[20] Choe HJ,Kim W,Cho NH.Steatotic liver disease predicts cardiovascular disease and advanced liver fibrosis: a community-dwelling cohort study with 20-year follow-up.Metabolism2024;153:155800

[21] Kim D,Cholankeril G.Steatotic liver disease-associated all-cause/cause-specific mortality in the United States.Aliment Pharmacol Ther2024;60:33-42

[22] Tamaki N,Wakabayashi S.Long-term clinical outcomes in steatotic liver disease and incidence of liver-related events, cardiovascular events and all-cause mortality.Aliment Pharmacol Ther2024;60:61-9

[23] Kim D,Cholankeril G.Metabolic dysfunction-associated steatotic liver disease and all-cause/cause-specific mortality among adults in the United States.J Hepatol2024;80:e79-81

[24] Ng CH,Ou KQ.IDDF2022-ABS-0132 Mafld and nafld in lean individuals. A prospective analysis of 12,505 lean individuals.Gut2022;71:A50.

[25] De A,Mehta M,Duseja A.Metabolic dysfunction-associated steatotic liver disease (MASLD) definition is better than MAFLD criteria for lean patients with NAFLD.J Hepatol2024;80:e61-2

[26] Ramírez-Mejía MM,Eslam M,Méndez-Sánchez N.Breaking new ground: MASLD vs. MAFLD-which holds the key for risk stratification?.Hepatol Int2024;18:168-78

[27] Wijarnpreecha K,Lundin SK.Higher mortality among lean patients with non-alcoholic fatty liver disease despite fewer metabolic comorbidities.Aliment Pharmacol Ther2023;57:1014-27 PMCID:PMC10682563

[28] Arvind A,Osganian SA.Risk of cardiovascular disease in individuals with nonobese nonalcoholic fatty liver disease.Hepatol Commun2022;6:309-19 PMCID:PMC8793991

[29] Ye Q,Yeo YH.Global prevalence, incidence, and outcomes of non-obese or lean non-alcoholic fatty liver disease: a systematic review and meta-analysis.Lancet Gastroenterol Hepatol2020;5:739-52

[30] Nso N,Ikram M.Cardiovascular morbidity and mortality in lean vs. non-lean MASLD: A comprehensive meta-analysis.Curr Prob Cardiology2024;49:102569

[31] Kang MK,Loomba R.Comparative associations of MASLD and MAFLD with the presence and severity of coronary artery calcification.Res Sq2024;rs.3:rs-3979461. PMCID:PMC10942572

[32] Chan KE,Chung CH.Longitudinal outcomes associated with metabolic dysfunction-associated steatotic liver disease: a meta-analysis of 129 studies.Clin Gastroenterol H2024;22:488-98.e14

[33] Targher G,Tilg H.MASLD: a systemic metabolic disorder with cardiovascular and malignant complications.Gut2024;73:691-702

[34] Durak H,Emlek N.FIB-4 liver fibrosis index correlates with aortic valve sclerosis in non-alcoholic population.Echocardiography2024;41:e15732

[35] Byrne CD.Non-alcoholic fatty liver disease-related risk of cardiovascular disease and other cardiac complications.Diabetes Obes Metab2022;24:28-43

[36] Anstee QM,Tilg H.Risk of cardiomyopathy and cardiac arrhythmias in patients with nonalcoholic fatty liver disease.Nat Rev Gastroenterol Hepatol2018;15:425-39

[37] Ren Z,Wesselius A,Brouwers MCGJ.Relationship between NAFLD and coronary artery disease: a mendelian randomization study.Hepatology2023;77:230-8 PMCID:PMC9970021

[38] Kumar J,Hasan M.Cardiovascular outcomes post bariatric surgery in patients with metabolic dysfunction-associated steatotic liver disease - a systematic review and meta-analysis.Clin Res Hepatol Gas2024;48:102261

[39] Wang G,Yang H,Zhou S.Impacts of bariatric surgery on adverse liver outcomes: a systematic review and meta-analysis.Surg Obes Relat Dis2023;19:717-26

[40] Solomon A,Cipăian CR.Interactions between metabolic syndrome, MASLD, and arterial stiffening: a single-center cross-sectional study.Healthcare2023;11:2696 PMCID:PMC10572783

[41] Lonardo A,Mantovani A.Hypertension, diabetes, atherosclerosis and NASH: cause or consequence?.J Hepatol2018;68:335-52

[42] Brunner KT,Massaro JM,Benjamin EJ.Increasing liver fat is associated with progression of cardiovascular risk factors.Liver Int2020;40:1339-43 PMCID:PMC8414370

[43] Brunner KT,Massaro JM,Benjamin EJ.Increasing liver fat is associated with incident cardiovascular risk factors.Clin Gastroenterol Hepatol2020;18:1884-6 PMCID:PMC7007830

[44] Srinivas AN,Santhekadur PK,Kumar DP.Extracellular vesicles as inflammatory drivers in NAFLD.Front Immunol2021;11:627424 PMCID:PMC7884478

[45] Chandrasekharan K.Genetics of non-alcoholic fatty liver and cardiovascular disease: implications for therapy?.Front Pharmacol2020;10:1413 PMCID:PMC6960381

[46] Petermann-rocha F,Boonpor J.Associations between an inflammatory diet index and severe non-alcoholic fatty liver disease: a prospective study of 171,544 UK Biobank participants.BMC Med2023;21:123 PMCID:PMC10071692

[47] Khan A,Ishaq M.Understanding the effects of gut microbiota dysbiosis on nonalcoholic fatty liver disease and the possible probiotics role: recent updates.Int J Biol Sci2021;17:818-33 PMCID:PMC7975705

[48] Lonardo A,Osna N.Effect of cofactors on NAFLD/NASH and MAFLD. A paradigm illustrating the pathomechanics of organ dysfunction.Metab Target Organ Damage2022;2:12 PMCID:PMC9453927

[49] Mauvais-Jarvis F,Barnes PJ.Sex and gender: modifiers of health, disease, and medicine.The Lancet2020;396:565-82 PMCID:PMC7440877

[50] Desai R,Vasavada A.Sex and racial disparities in non-alcoholic fatty liver disease-related cardiovascular events: national inpatient sample analysis (2019).World J Cardiol2024;16:137-48 PMCID:PMC10989223

[51] Kammerlander AA,Mahoney TF.Sex differences in the associations of visceral adipose tissue and cardiometabolic and cardiovascular disease risk: the Framingham heart study.JAHA2021;10:e019968 PMCID:PMC8483556

[52] Polman R,Uysal OF,Linz D.Cardiovascular disease and risk in COPD: a state of the art review.Expert Rev Cardiovasc Ther2024;22:177-91

[53] Lonardo A,Fabbri LM.Chronic obstructive pulmonary disease (COPD) and metabolic fatty liver syndromes: a dangerous but neglected liaison.Metab Target Organ Damage2022;2:6

[54] Viglino D,Bailly S.Impact of non-alcoholic fatty liver disease on long-term cardiovascular events and death in chronic obstructive pulmonary disease.Sci Rep2018;8:16559 PMCID:PMC6224555

[55] Lonardo A.Association of NAFLD/NASH, and MAFLD/MASLD with chronic kidney disease: an updated narrative review.Metab Target Organ Damage2024;4:16

[56] Miyamori D,Sato T.Coexistence of metabolic dysfunction-associated fatty liver disease and chronic kidney disease is a more potent risk factor for ischemic heart disease.JAHA2023;12:e030269 PMCID:PMC10382120

[57] Loria P,Bellentani S.NAFLD Expert Committee of the Associazione Italiana per lo studio del FegatoPractice guidelines for the diagnosis and management of nonalcoholic fatty liver disease. A decalogue from the Italian association for the study of the liver (AISF) expert committee.Dig Liver Dis2010;42:272-82.

[58] Dunn W,Wingard DL.Suspected nonalcoholic fatty liver disease and mortality risk in a population-based cohort study.Am J Gastroenterol2008;103:2263-71 PMCID:PMC2574666

[59] Söderberg C,Askling J.Decreased survival of subjects with elevated liver function tests during a 28-year follow-up.Hepatology2010;51:595-602

[60] Ekstedt M,Nasr P.Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up.Hepatology2015;61:1547-54

[61] Spahillari A,Defilippi C.The association of lean and fat mass with all-cause mortality in older adults: the cardiovascular health study.Nutr Metab Cardiovas2016;26:1039-47 PMCID:PMC5079822

[62] Targher G,Lonardo A,Barbui C.Non-alcoholic fatty liver disease and risk of incident cardiovascular disease: a meta-analysis.J Hepatol2016;65:589-600

[63] Stefan N,Targher G.Role of steatotic liver disease in prediction and prevention of cardiometabolic diseases.Nat Rev Gastroenterol Hepatol2024;21:136-7

[64] Li M,Zhang X,Li H.NAFLD: an emerging causal factor for cardiovascular disease.Physiology2023;38:255-65

[65] Li W,McPherson S.National study of NAFLD management identifies variation in delivery of care in the UK between 2019 to 2022.JHEP Rep2023;5:100897 PMCID:PMC10654022

[66] Driessen S,Anker SD.Metabolic dysfunction-associated steatotic liver disease and the heart.Hepatology2023;Online ahead of print.

[67] Aller R,lo Iacono O.Documento de consenso. Manejo de la enfermedad hepática grasa no alcohólica (EHGNA). Guía de práctica clínica.Gastroenterología y Hepatología2018;41:328-49

[68] Association for the Study of the Liver (EASL), European Association for the Study of Diabetes (EASD), European Association for the Study of Obesity (EASO). EASL-EASD-EASO clinical practice guidelines for the management of non-alcoholic fatty liver disease.J Hepatol2016;64:1388-402.

[69] Rinella ME,Siddiqui MS.AASLD practice guidance on the clinical assessment and management of nonalcoholic fatty liver disease.Hepatology2023;77:1797-835 PMCID:PMC10735173

[70] Cusi K,Barb D.American association of clinical endocrinology clinical practice guideline for the diagnosis and management of nonalcoholic fatty liver disease in primary care and endocrinology clinical settings.Endocrine Practice2022;28:528-62

[71] Visseren FLJ,Smulders YM.ESC Scientific Document Group2021 ESC guidelines on cardiovascular disease prevention in clinical practice.Eur Heart J2021;42:3227-337

[72] Ren Z,Stehouwer CD.Cardiovascular implications of metabolic dysfunction-associated fatty liver disease.Endocrin Metab Clin2023;52:459-68

[73] Chiang CH,Chan WL,Leu HB.The severity of non-alcoholic fatty liver disease correlates with high sensitivity C-reactive protein value and is independently associated with increased cardiovascular risk in healthy population.Clin Biochem2010;43:1399-404.

[74] Lonardo A,Targher G.Diagnosis and management of cardiovascular risk in nonalcoholic fatty liver disease.Expert Rev Gastroent2015;9:629-50

[75] Ichikawa K,Osawa K.Prognostic value of non-alcoholic fatty liver disease for predicting cardiovascular events in patients with diabetes mellitus with suspected coronary artery disease: a prospective cohort study.Cardiovasc Diabetol2021;20:8 PMCID:PMC7791695

[76] Kweon Y,Kim A.Prediction of cardiovascular risk using nonalcoholic fatty liver disease scoring systems.Healthcare2021;9:899 PMCID:PMC8303122

[77] Tsou M.Gender-based association of coronary artery calcification and framingham risk score with non-alcoholic fatty liver disease and abdominal obesity in taiwanese adults, a cross-sectional study.Front Cardiovasc Med2022;9:803967 PMCID:PMC8928543

[78] Zhou H,Ni J.Prevalence of cardiovascular risk factors in non-menopausal and postmenopausal inpatients with type 2 diabetes mellitus in China.BMC Endocr Disord2019;19:98 PMCID:PMC6787985

[79] Wang J.Commentary: of women, liver, and heart.Metab Target Organ Damage2023;3:14

[80] Ballestri S,Girolamo MD,Capitelli M.Liver fibrosis in nonalcoholic fatty liver disease patients: noninvasive evaluation and correlation with cardiovascular disease and mortality.Metab Target Organ Damage2023;3:1

[81] Kim Y,Lee JS.Cardiovascular risk is elevated in lean subjects with nonalcoholic fatty liver disease.Gut and Liver2022;16:290-9 PMCID:PMC8924809

[82] Han E,Kim YD.Nonalcoholic fatty liver disease and sarcopenia are independently associated with cardiovascular risk.Am J Gastroenterol2020;115:584-95

[83] Zhang P,Zhang W.Metabolic-associated fatty liver disease and the risk of cardiovascular disease.Clin Res Hepatol Gas2023;47:102063

[84] Chun HS,Lee JS.Metabolic dysfunction associated fatty liver disease identifies subjects with cardiovascular risk better than non-alcoholic fatty liver disease.Liver Int2023;43:608-25

[85] Semmler G,Wernly S.Insulin resistance and central obesity determine hepatic steatosis and explain cardiovascular risk in steatotic liver disease.Front Endocrinol2023;14:1244405 PMCID:PMC10570507

[86] Martínez-arranz I,Noureddin M.Metabolic subtypes of patients with NAFLD exhibit distinctive cardiovascular risk profiles.Hepatology2022;76:1121-34 PMCID:PMC9790568

[87] Lauridsen BK,Kristensen TS.Liver fat content, non-alcoholic fatty liver disease, and ischaemic heart disease: mendelian randomization and meta-analysis of 279013 individuals.Eur Heart J2018;39:385-93

[88] Treeprasertsuk S,Adams LA,St Sauver J.The Framingham risk score and heart disease in nonalcoholic fatty liver disease .Liver Int2012;32:945-50 PMCID:PMC3348257

[89] Golabi P,Paik J,Mishra A.Mortality risk detected by atherosclerotic cardiovascular disease score in patients with nonalcoholic fatty liver disease.Hepatol Commun2019;3:1050-60 PMCID:PMC6671783

[90] Mellemkjær A,Haldrup D,Thomsen KL.Management of cardiovascular risk in patients with metabolic dysfunction-associated steatotic liver disease.Eur J Intern Med2024;122:28-34

[91] Lonardo A.Renaming NAFLD to MAFLD: could the LDE system assist in this transition?.J Clin Med2021;10:492 PMCID:PMC7866816

[92] Thiele M,Graupera I.Screening for liver fibrosis: lessons from colorectal and lung cancer screening.Nat Rev Gastroenterol Hepatol2024;21:517-27

[93] Niederseer D,Bachmayer S.Diagnosis of non-alcoholic fatty liver disease (NAFLD) is independently associated with cardiovascular risk in a large austrian screening cohort.J Clin Med2020;9:1065 PMCID:PMC7230765

[94] Simon TG,Zheng H.Model for end-stage liver disease Na Score predicts incident major cardiovascular events in patients with nonalcoholic fatty liver disease.Hepatol Commun2017;1:429-38 PMCID:PMC5659323

[95] Mangla N,Caussy C.Liver stiffness severity is associated with increased cardiovascular risk in patients with type 2 diabetes.Clin Gastroenterol H2020;18:744-6.e1 PMCID:PMC6984972

[96] Kanwal F,Adams LA.Clinical care pathway for the risk stratification and management of patients with nonalcoholic fatty liver disease.Gastroenterology2021;161:1657-69 PMCID:PMC8819923

[97] Sterling RK,Duarte-Rojo A.AASLD practice guideline on blood-based non-invasive liver disease assessments of hepatic fibrosis and steatosis.Hepatology2024;Online ahead of print:

[98] Henson JB,Kaplan A,Masia R.Advanced fibrosis is associated with incident cardiovascular disease in patients with non-alcoholic fatty liver disease.Aliment Pharmacol Ther2020;51:728-36 PMCID:PMC7069774

[99] Vilar-gomez E,Wai-sun Wong V.Fibrosis severity as a determinant of cause-specific mortality in patients with advanced nonalcoholic fatty liver disease: a multi-national cohort study.Gastroenterology2018;155:443-457.e17

[100] Cardoso CRL,Leite NC.Prognostic impact of liver fibrosis and steatosis by transient elastography for cardiovascular and mortality outcomes in individuals with nonalcoholic fatty liver disease and type 2 diabetes: the Rio de Janeiro Cohort Study.Cardiovasc Diabetol2021;20:193 PMCID:PMC8464106

[101] Shili-masmoudi S,Hiriart J.Liver stiffness measurement predicts long-term survival and complications in non-alcoholic fatty liver disease.Liver Int2020;40:581-9

[102] Arai T,Tsubota A.Liver fibrosis is associated with carotid atherosclerosis in patients with liver biopsy-proven nonalcoholic fatty liver disease.Sci Rep2021;11:15938. PMCID:PMC8342487

[103] Arai T,Tsubota A.Factors influencing subclinical atherosclerosis in patients with biopsy-proven nonalcoholic fatty liver disease.PLoS ONE2019;14:e0224184 PMCID:PMC6853607

[104] Sonaglioni A,Nicolosi GL,Rumi MG.Left ventricular strain predicts subclinical atherosclerosis in nonadvanced nonalcoholic fatty liver disease patients.Eur J Gastroen Hepat2022;34:707-16

[105] Anstee QM,Nitze LM.Prognostic utility of fibrosis-4 index for risk of subsequent liver and cardiovascular events, and all-cause mortality in individuals with obesity and/or type 2 diabetes: a longitudinal cohort study.Lancet Reg Health Eur2024;36:100780 PMCID:PMC10769893

[106] Baratta F,Angelico F.Nonalcoholic fatty liver disease and fibrosis associated with increased risk of cardiovascular events in a prospective study.Clin Gastroenterol H2020;18:2324-31.e4

[107] Shao C,Li F.Early predictors of cardiovascular disease risk in nonalcoholic fatty liver disease: non-obese versus obese patients.Dig Dis Sci2020;65:1850-60

[108] Wu T,Shao C.The ability of lipoprotein (a) level to predict early carotid atherosclerosis is impaired in patients with advanced liver fibrosis related to metabolic-associated fatty liver disease.Clin Transl Gastroenterol2022;13:e00504 PMCID:PMC10476839

[109] You SC,Kim SU.Hepatic fibrosis assessed using transient elastography independently associated with coronary artery calcification.J Gastroenterol Hepatol2015;30:1536-42

[110] Yu X,Tong Y,Song Z.Usefulness of controlled attenuation parameter and liver stiffness measurement for detecting increased arterial stiffness in asymptomatic populations in China.Medicine2020;99:e23360 PMCID:PMC7710246

[111] Hanafy AS,Ahmed AF.Multifocal fatty liver disease, insulin resistance and carotid atherosclerosis: exploring the interrelated relationship.J Ultrason2018;18:302-9. PMCID:PMC6444317

[112] Kim H,Joo SK.Association of arterial stiffness with the histological severity of nonalcoholic fatty liver disease.Hepatol Int2020;14:1048-56

[113] Park JG,Verma KK.Liver stiffness by magnetic resonance elastography is associated with increased risk of cardiovascular disease in patients with non-alcoholic fatty liver disease.Aliment Pharmacol Ther2021;53:1030-7 PMCID:PMC8514119

[114] Tan EC,Chan W.Association between non-alcoholic fatty liver disease evaluated by transient elastography with extracranial carotid atherosclerosis in a multiethnic Asian community.JGH Open2019;3:117-25 PMCID:PMC6487823

[115] Tamaki N,Kurosaki M, Izumi N; MRCH Liver Study Group..Risk difference of liver-related and cardiovascular events by liver fibrosis status in nonalcoholic fatty liver disease.Clin Gastroenterol H2022;20:1171-1173.e2 PMCID:PMC8761224

[116] Mózes FE,Selvaraj EA.LITMUS InvestigatorsDiagnostic accuracy of non-invasive tests for advanced fibrosis in patients with NAFLD: an individual patient data meta-analysis.Gut2022;71:1006-19 PMCID:PMC8995830

[117] Han S,Lee B.Accuracy of noninvasive scoring systems in assessing liver fibrosis in patients with nonalcoholic fatty liver disease: a systematic review and meta-analysis.Gut Liver2022;16:952-63 PMCID:PMC9668505

[118] Younossi ZM,Felix S.The combination of the enhanced liver fibrosis and FIB-4 scores to determine significant fibrosis in patients with nonalcoholic fatty liver disease.Aliment Pharmacol Ther2023;57:1417-22

[119] Gosalia D,Stanicic F.Accuracy of noninvasive diagnostic tests for the detection of significant and advanced fibrosis stages in nonalcoholic fatty liver disease: a systematic literature review of the US studies.Diagnostics2022;12:2608 PMCID:PMC9689671

[120] Golabi P,Harring M,Kabbara K.Prevalence of high and moderate risk nonalcoholic fatty liver disease among adults in the United States, 1999-2016.Clin Gastroenterol Hepatol2022;20:2838-2847.e7

[121] Pisto P,Bloigu R,Kesäniemi YA.Fatty liver predicts the risk for cardiovascular events in middle-aged population: a population-based cohort study.BMJ Open2014;4:e004973 PMCID:PMC3963104

[122] Kim K,Han K.Association of non-alcoholic fatty liver disease with cardiovascular disease and all cause death in patients with type 2 diabetes mellitus: nationwide population based study.BMJ2024;384:e076388 PMCID:PMC10862140

[123] Yoshioka Y,Yatsuji S.Nonalcoholic steatohepatitis: cirrhosis, hepatocellular carcinoma, and burnt-out NASH.J Gastroenterol2004;39:1215-8

[124] Van der Poorten D,Ramezani-Moghadam M.Hepatic fat loss in advanced nonalcoholic steatohepatitis: are alterations in serum adiponectin the cause?.Hepatology2013;57:2180-8

[125] Fedchuk L,Pais R,Housset C.the LIDO Study GroupPerformance and limitations of steatosis biomarkers in patients with nonalcoholic fatty liver disease.Aliment Pharmacol Ther2014;40:1209-22

[126] Lonardo A,Bedogni G,Tiribelli C.The fatty liver index (FLI) 15 years later: a reappraisal.Metab Target Organ Damage2021;1:10

[127] Park CC,Hernandez C.Magnetic resonance elastography vs transient elastography in detection of fibrosis and noninvasive measurement of steatosis in patients with biopsy-proven nonalcoholic fatty liver disease.Gastroenterology2017;152:598-607.e2 PMCID:PMC5285304

[128] Hernaez R,Bonekamp S.Diagnostic accuracy and reliability of ultrasonography for the detection of fatty liver: a meta-analysis.Hepatology2011;54:1082-90 PMCID:PMC4197002

[129] Ballestri S,Byrne CD,Targher G.Diagnostic accuracy of ultrasonography for the detection of hepatic steatosis: an updated meta-analysis of observational studies.Metab Target Organ Damage2021;1:7

[130] Allan PL,Lee AJ.Relationship between carotid intima-media thickness and symptomatic and asymptomatic peripheral arterial disease: the Edinburgh artery study.Stroke1997;28:348-53

[131] Bakhshi H,Yang X.Progression of Coronary artery calcium and incident heart failure: the multi-ethnic study of atherosclerosis.JAHA2017;6:e005253 PMCID:PMC5533017

[132] Fuchs A,Sigvardsen PE.Subclinical coronary atherosclerosis and risk for myocardial infarction in a danish cohort: a prospective observational cohort study.Ann Intern Med2023;176:433-42

[133] Geurts S,Papageorgiou G,Kavousi M.Subclinical measures of peripheral atherosclerosis and the risk of new-onset atrial fibrillation in the general population: the Rotterdam study.JAHA2022;11:e023967 PMCID:PMC9075211

[134] Heffernan KS,Xu J,Churilla JR.Estimated pulse wave velocity and incident heart failure and its subtypes: Findings from the multi-ethnic study of atherosclerosis.Am Heart J Plus2023;25:100238 PMCID:PMC9983630